Daewoong Pharmaceutical and Apicell Therapeutics Collaborate with Seoul National University Hospital in Regenerative Medicine and Advanced Biopharmaceuticals
[Asia Economy Reporter Lee Gwan-joo] Daewoong Pharmaceutical and Apicell Therapeutics are collaborating with Seoul National University Hospital in the fields of regenerative medicine and advanced biopharmaceuticals.
Daewoong Pharmaceutical and Apicell Therapeutics announced on the 8th that they have signed a memorandum of understanding (MOU) with Seoul National University Hospital to cooperate on building regenerative medicine infrastructure and clinical research for advanced biopharmaceuticals.
Through this agreement, the three institutions plan to collaborate on ▲attracting domestic and international research projects ▲discovering, preserving, and industrializing intellectual property ▲establishing regenerative medicine infrastructure and clinical research and development for advanced biopharmaceuticals with world-class competitiveness ▲providing information and consulting related to research and development and technology exchange ▲training research personnel and mutual exchange.
Cooperation with Seoul National University Hospital is expected to accelerate the advanced biopharmaceutical development projects led by Daewoong Pharmaceutical and Apicell Therapeutics. Last year, Daewoong Pharmaceutical received approval from the Ministry of Food and Drug Safety and entered the contract development and manufacturing business for advanced biopharmaceuticals. Additionally, Apicell Therapeutics, a joint venture established by Daewoong Pharmaceutical and the UK-based Abzena, is developing next-generation cell therapies with enhanced efficacy by combining Daewoong’s stem cell platform (DW-MSC) and Abzena’s Affimer® technology.
Jeon Seung-ho, CEO of Daewoong Pharmaceutical, stated, “We are confident to collaborate with Seoul National University Hospital, the top medical institution in Korea, in regenerative medicine and advanced biopharmaceuticals, which are representative future industries in the pharmaceutical and medical fields. We will devote ourselves further to research and development through this agreement to contribute to improving the quality of life for the public.”
Hot Picks Today
"Most Americans Didn't Want This"... Americans Lose 60 Trillion Won to Soaring Fuel Costs
- "Striking Will Lead to Regret": Hyundai-Kia Employees Speak Out... Uneasy Stares Toward Samsung Union
- Man in His 40s Who Kept Girlfriend's Body for a Year After Murder Sentenced to 30 Years in Prison Again on Appeal
- Despite Captivating the Nation for Over a Month... "Timmy" the Whale Ultimately Found Dead
- "If You Booked This Month, You Almost Lost Out... Why You Should Wait Until 'This Day' Before Paying for Flight Tickets"
Kim Yeon-soo, Director of Seoul National University Hospital, said, “We are pleased to leverage the cutting-edge research and development capabilities of Daewoong Pharmaceutical and Apicell Therapeutics in the pharmaceutical and bio sectors. Through this cooperation, we will accelerate the establishment of regenerative medicine infrastructure and clinical research development with world-class competitiveness.”
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
